ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Abstract: FR-PO743

Evaluation of Albumin Loss During Hemodialysis with Theranova® Medium Cut-Off (MCO) Dialyzer: Six Months Follow-Up

Session Information

Category: Dialysis

  • 701 Dialysis: Hemodialysis and Frequent Dialysis

Authors

  • Marchionna, Nicola, S Bortolo Hosp, Vicenza, Italy
  • Samoni, Sara, S Bortolo Hosp, Vicenza, Italy
  • Neri, Mauro, IRRIV, Vicenza, Italy
  • Lorenzin, Anna, IRRIV, Vicenza, Italy
  • Brendolan, Alessandra, S Bortolo Hosp, Vicenza, Italy
  • Zanella, Monica, S Bortolo Hosp, Vicenza, Italy
  • Ronco, Claudio, S Bortolo Hosp, Vicenza, Italy
Background

Theranova® medium cut-off (MCO) dialyzer is an innovative membrane designed to expand the spectrum of medium molecules removal, beyond standard high-flux dialysis, using conventional hemodialysis (HD) infrastructure. It represents a novel method to remove uremic toxins in an increased range of molecular weight (MW).

Methods

The purpose of this observational study was to evaluate the safety of treatment in terms of albumin removal, evaluating the albumin concentrations in plasma and dialysate. Six patients on chronic HD were observed for a period of six months.
Each patient was treated with Theranova® 400 filter (PAES/PVP membrane, 1.7 m2 surface area, Baxter) in dialysis bicarbonate 4 h Qd 500 ml/min. Pre-treatment patient albuminemia and protein loss at the end of the treatment (dialysate sample) were assessed at the first treatment, one week, one month, three and six months after.

Results

Serum levels of predialitic albumin remained constant throughout the observation period (figure). Protein loss in each hemodialysis session was similar or lower than in HD bicarbonate treatments with high flux membranes, previously tested (3.7 ± 2.2 g).

Conclusion

In addition to a high efficiency in low and medium MW uremic toxins removal, in this study Theranova medium cut-off filters demonstrated not to cause an increased protein loss in comparison with a standard high flux dialyzer